Skip to main content

Table 1 Patient Characteristics

From: Clinical utility of cardiovascular magnetic resonance imaging in patients with implantable cardioverter defibrillators presenting with electrical instability or worsening heart failure symptoms

 All patients (n = 208)Primary prevention (n = 115)Secondary prevention (n = 93)p–value
Age, years60 ± 1260 ± 1159 ± 130.532
Gender, male, n(%)174 (84)98 (85)76 (82)0.498
BMI, kg/m228.6 ± 5.129.2 ± 5.327.9 ± 4.80.062
Hypertension, n(%)144 (69)80 (70)64 (69)0.907
Diabetes, n(%)46 (22)32 (28)14 (15)0.027
CHA2DS2–VASc Score2.7 ± 1.42.8 ± 1.22.4 ± 1.50.006
NYHA class1.9 ± 0.92.1 ± 0.91.6 ± 1.00.001
Known CAD, n(%)83 (40)52 (45)31 (33)0.082
Severity of CAD   0.178
 Single–vessel, n(%)31 (37)18 (35)13 (42) 
 Multi–vessel, n(%)52 (63)34 (65)18 (58) 
Electrical instability   0.009
  ≤ 2 adequate ATP/shock(s), n(%)23 (11)16 (14)7 (8) 
 Electrical storm, n(%)107 (51)53 (46)54 (58) 
 Below detection, n(%)11 (5)3 (3)8 (9) 
 Inadequate ATP/shock(s), n(%)15 (7)6 (5)9 (10) 
Prior VT ablation, n(%)50 (24)16 (14)34 (37)< 0.001
Antiarrhythmic drugs
 Betablockers, n(%)189 (91)104 (90)85 (91)0.811
 Class I, n(%)14 (7)5 (4)9 (10)0.127
 Class III, n(%)60 (29)31 (27)29 (31)0.504
Device characteristics   0.070
 S–ICD, n(%)6 (3)5 (4)1 (1) 
 Single chamber ICD, n(%)101 (49)55 (48)46 (49) 
 Dual chamber ICD, n(%)65 (31)30 (26)35 (38) 
 CRT–D, n(%)36 (17)25 (22)11 (12) 
MR-conditional devices, n(%)94 (45)48 (42)46 (49)0.266
 Time since ICD implantation, months58.9 ± 50.056.4 ± 42.461.9 ± 58.20.436
 Range, months1.4–240.41.6–225.01.4–240.4 
  1. Values are mean ± SD or n (%); p-values are given for the comparison of primary versus secondary prevention. BMI body mass index; CAD coronary artery disease; ATP antitachycardia pacing; VT ventricular tachycardia; ICD implanted cardioverter defibrillator; S–ICD subcutaneous implantable cardioverter defibrillator; CRT–D cardiac resynchronization therapy defibrillator, MR magnetic resonance